Belite Bio Inc ADR

Yahoo Finance • 17 days ago

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024

Virtual Investor Conferences NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Tuesday, September 24 and Wednesday, September 25, fea... Full story

Yahoo Finance • 10 months ago

Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference

SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significan... Full story

Yahoo Finance • 11 months ago

Belite Bio to Participate in the BTIG Ophthalmology Day

SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significa... Full story

Yahoo Finance • 11 months ago

Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results

Completed enrollment in pivotal Phase 3 “DRAGON” trial for Tinlarebant in adolescent Stargardt disease (“STGD1”) with 104 subjects enrolled across 11 countries worldwide First subject dosed with Tinlarebant in pivotal global Phase 3 “PHOEN... Full story

Yahoo Finance • 11 months ago

Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results

SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significan... Full story

Yahoo Finance • 11 months ago

Belite Bio, Inc. to present at the Deutsche Bank ADR Virtual Investor Conference on 8 November 2023

SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ:BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significan... Full story

Yahoo Finance • 11 months ago

Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting

Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (D... Full story

Yahoo Finance • 11 months ago

国际公司将于 2023 年 11 月 8 日至 9 日在 Deutsche Bank 存托凭证虚拟投资者会议上进行网络直播

纽约, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Deutsche Bank 今天公布了将于 11 月 8 日（周三）和 11 月 9 日（周四）举行的存托凭证虚拟投资者会议 (“dbVIC”) 的阵容，其中包括在美国实施美国存托凭证 (ADR) 计划的国际公司的网络直播演示。 来自澳大利亚、中国、法国、德国、希腊、香港、荷兰、菲律宾和台湾的参与公司代表将在正式演示中回答问题，并将通过虚拟贸易展位与投资者互动。该会议面向对非美国公司感兴趣的各... Full story

Yahoo Finance • 11 months ago

国際企業、2023年11月8日と9日にドイツ銀行　（Deutsche Bank） の預託証券バーチャル投資家カンファレンスでライブウェブキャストを主催

ニューヨーク発, Nov. 02, 2023 (GLOBE NEWSWIRE) -- ドイツ銀行は本日、11月8日水曜日と9日木曜日に開催される、米国預託証券 (ADR) プログラムを持つ国際企業のライブウェブキャストプレゼンテーションを特集する預託証券バーチャル投資家会議 (「dbVIC」) のラインナップを発表した。 オーストラリア、中国、フランス、ドイツ、ギリシャ、香港、オランダ、フィリピン、台湾に拠点を置く参加企業の代表者が正式なプレゼンテーションで質問に答え... Full story

Yahoo Finance • 11 months ago

Syarikat antarabangsa akan anjurkan siar web secara langsung di Persidangan Pelabur Maya Resit Pemegang Simpanan Deutsche Bank pada 8 dan 9 November 2023

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Deutsche Bank hari ini umumkan barisan untuk Persidangan Pelabur Maya Resit Pemegang Simpanan (“dbVIC”) pada hari Rabu, 8 November dan Khamis, 9 November, yang menampilkan pembentangan siar web... Full story

Yahoo Finance • 11 months ago

글로벌 기업들, 11월 8일과 9일 도이치뱅크(Deutsche Bank)의 예탁증서 가상투자자 컨퍼런스 (dbVIC)에서 라이브 웹캐스트 진행 예정

뉴욕, Nov. 02, 2023 (GLOBE NEWSWIRE) -- 도이치뱅크(Deutsche Bank)는 11월 8일(수)과 9일(목) 열리는 '예탁증서 가상 투자자 컨퍼런스(Depositary Receipts Virtual Investor Conference, 이하 dbVIC) 참가기업들의 라인업을 오늘 발표했다. 본 행사는 미국에서 미국예탁증서(ADR) 프로그램을 운영하는 글로벌 기업들의 라이브 웹캐스트 프레젠테이션... Full story

Yahoo Finance • 11 months ago

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Wednesday, November 8 and Thursday, November 9, featuring live webcast presentation... Full story

Yahoo Finance • 11 months ago

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 8th and 9th, 2023

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Wednesday, November 8 and Thursday, November 9, featuring live webcast presentation... Full story

Yahoo Finance • 11 months ago

Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting

Two-year data from the two-year Phase 1b/2 trial of Tinlarebant (LBS-008) in adolescent Stargardt Disease (STGD1) to be presentedA two-year global Phase 3 trial in adolescent STGD1 (the “DRAGON” study) and a two-year global Phase 3 trial i... Full story

Yahoo Finance • last year

Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results

In 18-month interim data from ongoing 2-year, Phase 2 Stargardt disease (“STGD1”) trial (“LBS-008-CT02”), we continued to observe that oral Tinlarebant is safe and well tolerated in adolescent STGD1 subjects A continued trend of slowing ex... Full story

Yahoo Finance • last year

Belite Bio to Host Webcast on May 11, 2023 to Discuss First Quarter 2023 Financial Results

SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have signif... Full story

Yahoo Finance • last year

Belite Bio to Host Key Opinion Leader Webinar Discussing Progression of Childhood-onset STGD1 and Relevance of the Tinlarebant 18-month Phase 2 Data

The webinar will take place on Wednesday, May 10, 2023 at 1:00 PM ET SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical stage biopharmaceutical drug development company focused on advancing novel ther... Full story

Yahoo Finance • last year

Belite Bio to Host Key Opinion Leader Webinar on RBP4 Antagonist Tinlarebant in Late-Stage Development for Stargardt Disease 1

Virtual event on Wednesday, May 3rd at 1:00 PM ET will feature key opinion leader Hendrik Scholl, M.D. from the University of Basel, Switzerland 18-month interim efficacy and safety data from Belite Bio’s Phase 2 trial evaluating tinlareb... Full story

Yahoo Finance • 2 years ago

Belite Bio Reports Full-Year 2022 Operational Highlights and Financial Results

12-month interim data from the ongoing 2-year, Phase 2 Stargardt disease (STGD1) study continues to show halting or slowing of lesion growth; 18-month efficacy and safety update expected during the 2023 Association for Research in Vision a... Full story

Yahoo Finance • 2 years ago

Belite Bio to Host Webcast on April 3, 2023 to Discuss 2022 Full Year Financial Results

SAN DIEGO, March 31, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting eye diseases with significant unmet medical needs, will host a live webca... Full story